Last Close
Apr 08  •  04:00PM ET
29.73
Dollar change
+1.00
Percentage change
3.48
%
Index
RUT
P/E
1.57
EPS (ttm)
18.91
Insider Own
3.15%
Shs Outstand
18.31M
Perf Week
9.95%
Market Cap
549.21M
Forward P/E
7.13
EPS next Y
4.17
Insider Trans
-0.68%
Shs Float
17.89M
Perf Month
5.91%
Enterprise Value
447.55M
PEG
-
EPS next Q
0.84
Inst Own
87.82%
Perf Quarter
-31.31%
Income
367.02M
P/S
1.87
EPS this Y
-77.69%
Inst Trans
6.52%
Perf Half Y
2.87%
Sales
294.28M
P/B
1.39
EPS next Y
-4.09%
ROA
69.66%
Perf YTD
-30.59%
Book/sh
21.38
P/C
3.54
EPS next 5Y
-
ROE
185.94%
52W High
52.24 -43.09%
Perf Year
81.61%
Cash/sh
8.39
P/FCF
7.26
EPS past 3/5Y
- -
ROIC
88.58%
52W Low
15.50 91.81%
Perf 3Y
137.84%
Dividend Est.
-
EV/EBITDA
3.50
Sales past 3/5Y
34.76% 22.06%
Gross Margin
93.33%
Volatility
4.49% 4.08%
Perf 5Y
-10.45%
Dividend TTM
-
EV/Sales
1.52
EPS Y/Y TTM
1947.02%
Oper. Margin
42.63%
ATR (14)
1.31
Perf 10Y
19.88%
Dividend Ex-Date
-
Quick Ratio
2.30
Sales Y/Y TTM
64.15%
Profit Margin
124.72%
RSI (14)
57.23
Dividend Gr. 3/5Y
- -
Current Ratio
2.42
EPS Q/Q
1598.57%
SMA20
11.15%
Beta
1.28
Payout
0.00%
Debt/Eq
0.14
Sales Q/Q
21.19%
SMA50
-4.34%
Rel Volume
1.08
Prev Close
28.73
Employees
174
LT Debt/Eq
0.06
SMA200
-10.33%
Avg Volume
352.49K
Price
29.73
IPO
Nov 29, 2000
Option/Short
Yes / Yes
Trades
Volume
385,361
Change
3.48%
Date Action Analyst Rating Change Price Target Change
Nov-05-25Upgrade Jefferies Hold → Buy $42
Apr-03-23Resumed Piper Sandler Neutral $2
Jun-09-22Downgrade Citigroup Buy → Neutral
Jun-08-22Downgrade Piper Sandler Overweight → Neutral $7 → $1
Jun-08-22Downgrade Cantor Fitzgerald Overweight → Neutral $6 → $1
Mar-23-22Initiated B. Riley Securities Neutral $4
Nov-09-20Downgrade JP Morgan Overweight → Neutral
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Apr-07-26 08:05AM
Mar-31-26 08:05AM
Mar-04-26 12:02AM
Mar-03-26 06:02PM
05:15PM
04:18PM Loading…
04:18PM
04:01PM
10:00AM
Feb-27-26 08:32AM
Feb-26-26 10:00AM
Feb-25-26 08:05PM
Feb-24-26 10:00AM
09:02AM
08:05AM
Feb-18-26 08:12AM
08:59AM Loading…
Feb-16-26 08:59AM
Feb-03-26 08:05AM
Jan-28-26 11:24AM
Jan-16-26 10:26AM
08:55AM
Jan-12-26 08:05AM
Jan-09-26 08:05AM
Jan-08-26 12:21PM
09:36AM
Jan-07-26 12:31PM
08:45AM
08:05AM
Jan-06-26 10:00AM
05:33AM
Dec-07-25 09:30AM
12:00PM Loading…
Dec-05-25 12:00PM
Dec-03-25 04:00PM
09:40AM
Nov-27-25 09:15AM
Nov-26-25 08:05AM
Nov-17-25 01:38PM
08:05AM
Nov-12-25 08:05AM
Nov-06-25 12:20PM
12:00PM
Nov-05-25 12:01AM
Nov-04-25 05:25PM
04:22PM
04:01PM
Nov-03-25 09:05AM
07:57AM
Oct-31-25 01:53PM
Oct-29-25 08:05AM
Oct-15-25 09:40AM
Oct-14-25 09:35AM
Oct-08-25 08:05AM
Oct-03-25 08:05AM
Sep-29-25 07:09PM
10:04AM
09:40AM
Sep-26-25 09:35AM
Sep-25-25 11:26AM
Sep-18-25 11:25AM
Sep-17-25 02:27PM
Sep-11-25 09:48AM
Sep-09-25 12:00PM
Sep-08-25 02:45PM
Sep-05-25 09:09AM
Sep-03-25 02:02PM
Aug-27-25 01:57PM
Aug-26-25 08:05AM
Aug-25-25 02:03PM
10:15AM
09:15AM
Aug-22-25 09:04AM
Aug-20-25 12:45PM
Aug-15-25 09:50AM
Aug-12-25 09:15AM
09:11AM
Aug-08-25 12:20PM
10:00AM
09:15AM
06:09AM
Aug-07-25 02:00PM
09:55AM
09:15AM
Aug-06-25 03:29AM
Aug-05-25 06:10PM
05:04PM
04:01PM
Aug-04-25 10:00AM
Jul-31-25 10:00AM
Jul-30-25 12:10PM
09:55AM
09:40AM
Jul-29-25 08:05AM
Jul-10-25 11:14AM
Jul-07-25 08:05AM
May-29-25 09:40AM
May-28-25 09:55AM
08:05AM
May-22-25 05:20PM
May-14-25 09:55AM
May-13-25 09:40AM
May-10-25 11:55AM
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOOS WALTER HDirectorFeb 20 '26Option Exercise24.004,00096,00016,722Feb 24 04:58 PM
MOOS WALTER HDirectorFeb 20 '26Sale36.364,000145,44012,722Feb 24 04:58 PM
MOOS WALTER HDirectorFeb 20 '26Proposed Sale36.364,000145,440Feb 20 01:52 PM
RODRIGUEZ RAUL RCEO, PresidentJan 26 '26Option Exercise27.4080,0002,192,000285,243Feb 04 04:20 PM
Schorno Dean LEVP & Chief Financial OfficerDec 22 '25Option Exercise21.516,500139,78664,235Dec 29 08:06 PM